Invention Grant
- Patent Title: Superagonistic anti-CD28 antibodies
- Patent Title (中): 超强抗CD28抗体
-
Application No.: US12554180Application Date: 2009-09-04
-
Publication No.: US07939638B2Publication Date: 2011-05-10
- Inventor: Thomas Hanke , Martin Trischler , Christine Guntermann
- Applicant: Thomas Hanke , Martin Trischler , Christine Guntermann
- Applicant Address: RU Moscow
- Assignee: TheraMAB LLC.
- Current Assignee: TheraMAB LLC.
- Current Assignee Address: RU Moscow
- Agency: DLA Piper LLP (US)
- Main IPC: C07K16/00
- IPC: C07K16/00

Abstract:
The present invention relates to one or more nucleic acid(s) encoding a binding molecule specifically binding to a human CD28 molecule, comprising (a) a nucleic acid sequence encoding a VH region and a nucleic acid sequence encoding a VL region comprising CDRs in a human immunoglobulin framework, wherein (i) the CDRs of the VH region (CDR-H) comprise the amino acid sequences of SEQ ID NOS: 2 or 18 (CDR-H3), 4 or 20 (CDR-H2) and 6 or 22 (CDR-H1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 1 or 17 (CDR-H3), 3 or 19 (CDR-H2) and 5 or 21 (CDR-H1); and (ii) the CDRs of the VL region (CDR-L) comprise the amino acid sequences of SEQ ID NOS: 8 or 24 (CDR-L3), 10 or 26 (CDR-L2) and 12 or 28 (CDR-L1) or are encoded by the nucleic acid sequences of SEQ ID NOS: 7 or 23 (CDR-L3), 9 or 25 (CDR-L2) and 11 or 27 (CDR-L1); and (b) a nucleic acid sequence encoding the constant region of a human IgG1 or IgG4 antibody.
Public/Granted literature
- US20100168400A1 Superagonistic Anti-CD28 Antibodies Public/Granted day:2010-07-01
Information query